Tirzepatide

Tirzepatide was developed by Eli Lilly and Company and first detailed in scientific literature in 2018. It represents a breakthrough class of dual GIP and GLP-1 receptor agonists designed to address metabolic dysregulation. What it is: Tirzepatide is a synthetic peptide containing 39 amino acids, structurally based on the endogenous gastric inhibitory polypeptide (GIP) sequence, modified with a C20 fatty diacid moiety to enable once-weekly subcutaneous administration. It falls under the Metabolic category and is commonly known under brand names Mounjaro and Zepbound. Proposed Mechanisms & Research Findings: It acts as a dual agonist at both GIP and GLP-1 receptors, stimulating insulin secretion, improving insulin sensitivity, delaying gastric emptying, and reducing appetite. Research shows it achieves superior glycemic control and weight reduction compared to selective GLP-1 agonists. Regulatory & Safety Status: It is FDA approved for the treatment of Type 2 Diabetes (2022) and chronic weight management in adults with obesity (2023). Sourcing must be conducted via prescription from registered pharmacies; gray-market non-prescription research compounds carry high risks of contamination. Athletic & Anti-Doping Status: Tirzepatide is currently under WADA monitoring. It is not strictly prohibited unless specified by individual athletic commissions, but athletes must follow clinical use guidelines as it alters energy balance and body composition.